The increased expression and the oncogenic function of ZEB2‐AS1 were confirmed in several cancers, including hepatocellular carcinoma,21 bladder cancer,9 pancreatic cancer,22 colorectal cancer,23 and triple‐negative breast cancer.11 Here, ZEB2 is linked to urinary bladder carcinoma.